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Background: Thymosin beta 4 is a promising agent in preclinical regenerative and cardioprotection research. After
myocardial injury it improves cell survival, reduces inflammation and activates epicardial progenitor cells. The peptide is
also involved in cardiac purinergic signaling.
Methods: We investigated the peptide’s therapeutic potential in a mouse model for myocardial infarction and performed
microarray analysis in the early post-infarction period in order to identify new pathways for cardioprotection and
also studied its influence on soluble purinergic enzyme activity. In this study 69 mice underwent ligation of the
left anterior descending coronary artery. Thymosin beta 4 or vehicle was injected either intraperitoneally or
intramyocardially and the mice were followed for 2, 5, 7 or 28 days. Echocardiography was performed 2 and
28 days after infarction. Biochemical analyses were performed to measure apoptosis, cardiomyocyte hypertrophy and
inflammation.
Results: Treatment improved left ventricular function and reduced cardiac remodeling. The rate of apoptosis
and amount of cardiac inflammatory cells were similar between groups. Microarray data showed a significant
up-regulation of chitinase 3-like-1 and this was verified by quantitative RT-PCR. The activity of CD73 increased
gradually during the first week after infarction and was significantly higher in treated animals compared to
controls.
Conclusions: Thymosin beta 4 treatment had mild preventive effect on left ventricle remodeling after myocardial
infarction. Treated animals showed higher levels of CD73 activity and chitinase 3-like-1, which are novel molecules
possibly related to thymosin beta 4 mediated cardioprotection.
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Thymosin beta 4 (TB4) is a naturally occurring G-actin
sequestering peptide that has showed good cardioprotec-
tive potential in several animal studies. After myocardial
infarction (MI) it reduces infarct size and remodeling of
the left ventricle (LV) leading to improved cardiac func-
tion. It has also been shown to induce the migration of* Correspondence: ckjsta@utu.fi
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and is thought to aid in the repair of the heart after MI
[1]. The cellular mechanisms responsible for these
effects are partly mediated by phosphorylation of the
survival kinase Akt (protein kinase B). The activation of
the Akt pathway decreases cell necrosis and apoptosis as
well as inflammation after ischemic insult in the heart
[2]. Recently TB4 was linked to increased cell surface
ATP production by acting through extracellular ATP
synthase and it was speculated that the increase in localle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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purinergic signaling [3].
We wanted to test the effect of TB4 in a mouse MI
model using standard biochemical methods for assessing
cardioprotection and serial echocardiography to deter-
mine changes in left ventricular function and remodeling.
Previous studies have mostly relied on comparing end-
point imaging results with baseline studies or sham groups
[4–6]. Since infarct sizes with ligation models vary de-
pending on technical success we wanted to determine the
change in these parameters over time and compared early
and late functional and structural outcome after MI,
which better reflects disease progression. The influence of
TB4 on myocardial mRNA expression early after
infarction was investigated in order to identify new
targets and signaling pathways for TB4. In addition we
screened plasma samples for possible involvement of
soluble purine-converting enzymes in TB4-mediated
cardioprotection.
TB4 treatment reduced infarct expansion, left ven-
tricular remodeling and improved cardiac function. The
activity of the cardioprotective enzyme CD73 increased
and chitinase 3-like-1 (Ch3l1), a novel acute phase pro-
tein was up-regulated in treated animals. This may be
related to TB4 treatment or secondary to changes in the
inflammatory response after MI.
Methods
Animal experiments
MI was induced in 8–10 week-old male FVB/n mice by
permanent ligation of the left anterior descending artery
(LAD) [7]. The animals were pre-anesthetized in an incuba-
tion chamber using 5% isoflurane. Endotracheal intubation
was performed using a 22G venous cannula and the
animals were then connected to a ventilator (TOPO dual
mode ventilator, Kent Scientific, Torrington, CT, USA). The
respiratory rate was set to 100/min and anesthesia was
maintained using 1.5% isoflurane with an oxygen flow of
2 l/min. Hypothermia was prevented by keeping the mice
on a heating pad. The anterior part of the thorax was
shaved and the skin was disinfected. A longitudinal skin in-
cision was made to the left of the sternum and the intercos-
talspace was opened using an electric cauterization pen.
The ribs were retracted and the pericardium opened. For
ligation an 8-0 prolene suture was tied around the middle
portion of the LAD immediately below the left auricle.
Total occlusion was confirmed by visualization of paleness
in the apex of the heart. The ribs were approximated by a
5-0 figure-of-eight suture and the muscle and skin wounds-
were closed separately using 4-0 sutures. Anesthesia was
interrupted and the animals kept on mechanical venti-
lation until spontaneous breathing occurred. The
intubation tube was removed when motor activity
returned. Post-operatively the animals received three1 mg/kg injections of buprenorphine (Temgesic,
Schering-Plough, Espoo, Finland) every 8–10 h. The
animals were housed in individual cages with a 12/
12 h light-dark cycle and had ad libitum access to
food pellets and water. Sacrifice was performed by cer-
vical dislocation after CO2 asphyxiation. The thorax
was opened and the heart dissected and weighed. The
heart was cut into two equal sections along the long
axis of the heart perpendicular to the septal wall. The
anterior half was fixed in formalin and the posterior
half of the heart was snap frozen in liquid nitrogen
and stored at −80 °C.
Study groups
A total of 69 animals underwent ligation of the LAD
and were divided into long-term and short-term study
groups. For the long-term study, 45 animals were di-
vided into three groups and followed for 4 weeks. The
first group (n = 16) received daily intraperitoneal injec-
tions of TB4 (Genway Biotech, San Diego, CA, USA)
(6 mg/kg suspended in300 μl PBS) for 14 days. The
first injection was given 1 h following the procedure.
The second treatment group (n = 17) received three
doses of TB4 (400 ng suspended in 10 μl PBS) at 2, 7
and 14 days post-MI injected under echocardiographic
control into the peri-infarct area of the anterior left
ventricular wall. The control group (n = 12) received
daily intraperitoneal injections of saline for 14 days
post-MI.
The remaining 24 animals were included into the
short-term study and divided into TB4 treatment groups
(n = 5) and control groups (n = 3) and followed for 2, 5
and 7 days after MI. TB4 (6 mg/kg suspended in 300 μl
PBS) was administered intraperitoneally 1 h after the
procedure and then daily. The control animals received
equal volumes of plain PBS.
Echocardiography
In the 4 week study the animals underwent echocardiog-
raphy at 2 and 28 days post-MI by an investigator
blinded to group assignments. For imaging the animals
were pre-anesthetized quickly with 5% isoflurane and
placed on a heating pad. The animals were allowed to
breathe spontaneously and anesthesia was maintained
using 1.5% isoflurane administered through a nasal
mask. Echocardiography was performed using a high-
frequency small animal imaging platform (Vevo 2100,
Fujifilm VisualSonics Inc, Toronto, Ontario, Canada).
Parasternal longitudinal images at the level of the left
ventricular outflow tract were used for measuring left
ventricular dimensions and ejection fraction. Myocardial
infarct size was determined by measuring the longitu-
dinal length ratio of the akinetic myocardium with a wall
thickness less than 50% of the normal compared to
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ments were compared for determining progression of
LV remodeling and heart failure.
Histology and immunohistochemistry
Formalin fixed paraffin-embedded tissue samples were cut
in 5 μm thickness and stained with hematoxylin and eosin
for histological evaluation. Infarct sizes were determined
by measuring the length of the infarct area divided by the
length of the entire free left ventricular wall in one slide.
For cardiomyocyte hypertrophy measurement average
myocardial cell diameters were calculated in 10 high-
power (x40) visual fields of the preserved non-infarcted
myocardium of the anterior left ventricular wall and of the
peri-infarct area. Apoptotic cells in the infarct border zone
were quantified using TUNEL (terminal uDTP nick-end
labeling) assays as described previously [8]. In brief,
paraffin-embedded sections were transferred to glass-
slides and treated with sodium-citrate solution and then
digested with proteinase K in order to expose the DNA.
DNA strand breaks were then labeled with digoxigenin-
ddUTP and stained with alkaline phosphatase for
visualization. TUNEL-positive cells were counted in 5–
10 high-power visual fields (x40) per sample. Immuno-
histochemical staining was performed on paraffin-
embedded sections after antigen retrieval (microwaving
in citrate buffer pH 6.0) according to the manufacturer’s
instructions. The primary antibodies were rabbit poly-
clonal anti-Ki-67 (1:3000, clone AB9260, Millipore),
rabbit polyclonal anti-CD68 (1:100, cat. No. bs-0649R,
Bioss antibodies) and rabbit polyclonal anti-chitinase 3-
like-1 (1:5000, cat. No. bs-1093R-A350, Bioss antibodies).
The primary antibodies were detected with poly-HRP
anti-rabbit IgG (1:1000, Bright Vision). All histological
analyses were performed in a blinded manner.
Microarray analysis and qRT-PCR
Heart tissues samples from three treated and three
control animals at 2 days post-MI were processed for
microarray analysis. Tissues were lyced with Precellys®24
tissue homogenizer using 1.4 mm ceramic beads (CK14,
Precellys). Total RNA was isolated using a Nucleospin
RNA II kit (Macherey-Nagel, cat. No. 740955.250) ac-
cording to the manufacturer’s instructions. RNA quality
was assessed using a Bioanalyzer (Agilent), prior to
hybridization on IlluminaMouseWG-6 v2.0 Expression
BeadChip at the Functional Genomics Unit Biomedicum
(FuGU) core facility of the University Of Helsinki,
Finland. Unpaired t-test was used to detect differentially
expressed genes. Expression levels of Chitinase 3-like 1
was analyzed on samples from 3 animals in both groups
2 and 7 days after MI. Real time quantitative (qRT-PCR)
mRNA expression levels were measured with SYBR
Green real-time PCR using Reverse Transcriptase CoreKit (Eurogentec, cat. No. RT-RTCK-05) for cDNA syn-
thesis and SYBR Green Master Mix (Eurogentec, Mesa
Green qPCR Master Mix Plus for SYBR assay, cat. no.
RT-SY2X-06 +WOU) for PCR reaction. Samples were
measured with a CFX96 Touch Real-Time PCR Detection
System (Bio-Rad, CA, USA). Results were normalized
against the expression levels of two housekeeping genes,
β-actin and ribosomal S18, using CFX Manager™ software.
Primer sequences for each gene were: CHI3L1(forw) 5’-
GCA CAC CTC TAC TGA AGC CA-3’(rev) 5’-GCT
GGT GAA GTA GCA GAC CA-3’: ACTB(forw) 5’-GCA
AGC AGG AGT ACG ATG AG-3’ (rev) 5’- TAA CAG
TCC GCC TAG AAG CA-3’: RSB18(forw) GAT GGG
AAG TAC AGC CAG GT-3’ (rev) TTT CTT CAG CCT
CTC CAG GT-3’. All primers were from Oligomer
(Oligomer Oy, Helsinki, Finland).
Plasma ATP, ADP and soluble purine-converting enzymes
Plasma levels of circulating ATP, ADP and soluble
purine-converting enzymes were measured from TB4
treated and control animals at 2, 5 and 7 days post-MI.
For quantifying plasma ATP and ADP concentrations,
plasma aliquots (5 μl) were suspended in100 μl PBS,
heat inactivated and essentially measured as previously
described [9] using ATPlite assay kit (Perkin Elmer)
according to the manufacturer’s instructions. Samples
were transferred into two parallel white 96-well plates
along with (A) or without (B) 200 μM UTP and 5 U/ml
of NDP kinase from S. cerevisiae (Sigma). Sample set A
gives luminescence signal from both ATP and ADP and
set B only from ATP, which can be used to extract ADP
concentration in plasma samples. Plasma hemoglobin
concentrations, which did not exceed 4.0 mg/dl (data not
shown) were determined with Drabkin’s reagent (Sigma).
For analysis of soluble, purine-converting enzyme activities
plasma aliquots (10 μl) were suspended to RPMI-1640
media in 96-well flat bottom clear plates. Enzymatic
activities were determined at 37 °C in a final volume of
80 μl containing 4 mM β-glycerophosphate. Specific reac-
tion conditions were optimized for each enzyme separately:
(1) for ATPase, plasma suspension was incubated for
40 min with 300 μM [2,8-3H] ATP (American Radiola-
belled Chemicals, St. Louis, MO) as appropriate substrate;
(2) ADPase was assayed with 250 μM [2,8-3H] ADP (Per-
kin Elmer, Boston, MA) and incubated for 50 min with
10 μM P1,P5-Di(Adenosine-5’) Pentaphosphate (Ap5A,
Sigma) to inhibit backward adenylate kinase (AK) activity;
(3) ecto-5’-nucleotidase (CD73) activity was determined
after 40-min incubation with 250 μM [2-3H] AMP
(Amersham, UK); (2) AK and nucleoside diphosphate
kinase (NDPK) were assayed with 450 μM [3H] AMP
for 30 min or with 1000 μM [3H] ADP for 10 min as
respective phosphorus acceptors in the presence of
800-2000μMγ-phosphate-donating ATP. After selected
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sample aliquots of the mixture onto Alugram SIL G/
UV254 sheets (Macherey–Nagel, Duren, Germany).
3H-labeled nucleotides and nucleosides were sepa-
rated by thin-layer chromatography (TLC) using ap-
propriate solvent mixture: 1-butanol, iso-amyl alcohol,
diethylene glycol monoethylether, ammonia solution,
and milli-Q-aqua (9:6:18:9:15) and then quantified by
scintillation β-counting as previously [9].
Statistical analysis
Results are presented as means ± SD. Student’s t-test was
used for single comparative analysis and one-way ANOVA
with Tukey’s or Dunnett’s tests for multiple comparisons.
A p-value <0.05 was considered statistically significant in
all analyses.
Results
Survival and weight gain
In the long-term study 16 out of 45 animals died: 6 in
the intraperitoneal treatment group, 7 in the intramyo-
cardial treatment group and 3 in the control group. The
remaining 29 animals survived for the complete duration
of the study. All operated animals in the short-term
study completed the follow-up period. Most deaths were
considered cardiogenic as the most common finding at
autopsy was a ruptured left ventricular wall with
hemorrhage into the pleural and pericardial cavities.
Kaplan-Meier plots did not show statistically significant
mortality rates between the groups (p = 0.69). At 28 days
post-MI control animals had gained more weight than
treated animals. Change in body weight was otherwise
similar between the groups. Heart weight to body weight
ratios were similar at all different time points in all
groups (Table 1).
TB4 treatment reduces post-infarction remodeling and
improves LV function
Echocardiography was performed 2 days and 4 weeks
after infarction to determine left ventricular remodeling.
One animal in the intramyocardial and 2 animals in the
intraperitoneal TB4 treatment groups were excluded
from functional analysis due to persistent ventricularTable 1 Effect of thymosin beta 4 treatment on body and heart we







Body weight at day 0 (g) 25.8 ± 0.2 25.4 ± 1.9 24.2 ± 0.9
Δ body weight day 0 vs day 28 (g) −1.9 ± 2.3 −1.9 ± 1.1 −0.5 ± 0.9
Heart weight (mg) 114 ± 2 117 ± 3 118 ± 13
Heart to body weight ratio (mg/g) 4.8 ± 0.4 5.0 ± 0.2 5.1 ± 0.5
* = p < 0.05 compared to control, all other p = NS (mean ± SD)tachycardia during imaging. When comparing ejection
fraction (EF), end-systolic volume (ESV), end-diastolic
volume (EDV) and MI sizes at the two time-points, no
statistically significant differences were observed
between the groups (Table 2). The absolute changes in
these parameters over time were however significant in
favor of TB4 treated animals (Fig. 1). While EF in the
control group decreased by 10.1% during the follow-up
period only a 2.0% decrease in the intraperitoneal and a
6.7% increase in the intramyocardial treatment groups
were observed. Furthermore, infarct area expansion and
increase in ESV and EDV during follow-up was more
obvious in control animals than in either treatment
group.
Myocardial cell proliferation, hypertrophy, apoptosis and
cardiac inflammation
All samples showed very low numbers of cells positive
for the proliferation marker Ki-67 with no differences
between the control, intraperitoneal and intramyocar-
dial groups at 4 weeks (0.97 ± 0.12% versus 1.37 ±
0.38%, p = 0.42 and 1.4 ± 0.58%, p = 0.38). Cardiomyo-
cyte sizes, reflecting hypertrophy, were similar at
4 weeks both in the infarct region (27.1 ± 2.2 μm vs.
26.6 ± 3.1 μm, p = 0.91 and 24.4 ± 3.4 μm, p = 0.09 and
in the non-infarcted left ventricle (25.1 ± 2.3 μm vs.
24.6 ± 2 μm, p = 0.89 and 25.6 ± 3 μm, p = 0.93. In the
short-term study, infarct sizes were similar in control
and TB4 treated animals (Fig. 2a). The number of
TUNEL-positive apoptotic myocardial cells did not
differ at 2 days (7.2 ± 4.5 versus 8.4 ± 1.5 cells/visual
field, p = 0.75), 5 days (1.2 ± 0.5 vs. 1.1 ± 0.3 cells/visual
field, p = 0.74) or 7 days (0.7 ± 0.5 vs. 0.6 ± 0.4 cells/
visual field, p = 0.8) post-MI (Fig. 2b). There was an
increase in CD68 positive macrophages in both groups
between day 2 (3.6 ± 1.4 cells/field vs. 1.5 ± 1.1 cells/
field, p = 0.11), day 5 (11.0 ± 5.1 cells/field vs. 14.6 ±
9.5, p = 0.60) and day 7 (19.5 ± 8.4 cells/field vs. 24.8 ±
14.9 cells/field, p = 0.62) post-MI without significant
differences between the groups (Fig. 2c). These results
suggest that TB4 had no significant influence on pro-
grammed cell death or macrophage infiltration at the
time points observed.ight after myocardial infarction













24.6 ± 2.3 25.5 ± 1.3 25.5 ± 0.9 26.6 ± 1.5 27.9 ± 2.3 27.0 ± 1.3
−0.8 ± 0.7 0.4 ± 1.3 −2.5 ± 2.4 3.2 ± 1.0 1.5 ± 1.6* 2.1 ± 1.6
118 ± 7 134 ± 16 120 ± 11 152 ± 16 151 ± 26 148 ± 20
5.0 ± 0.4 5.2 ± 0.8 5.2 ± 0.3 5.1 ± 0.4 4.9 ± 0.5 5.1 ± 0.6







EF at day 2 post-MI (%) 42.5 ± 4.0 41.6 ± 2.6 39 ± 3.8
EF at day 28 post-MI (%) 38.2 ± 6.3 41.5 ± 3.9 41.2 ± 4.5
ESV at day 2 post-MI (μl) 43.3 ± 7.5 45.5 ± 5.2 48.7 ± 9.6
ESV at day 28 post-MI (μl) 58.5 ± 18 49 ± 7.0 51.7 ± 14.3
EDV at day 2 post-MI (μl) 75.2 ± 10.3 77.9 ± 8.4 79.3 ± 11.9
EDV at day 28 post-MI (μl) 93.3 ± 21.3 83.6 ± 7.5 86.9 ± 17.7
MI at day 2 post-MI by echo (%) 13.4 ± 5.7 17.7 ± 14.1 21 ± 8.9
MI at day 28 post-MI by echo (%) 21.7 ± 10 18 ± 10.5 20.5 ± 9.8
All p = NS (mean ± SD)
EF left ventricle ejection fraction, ESV left ventricle end-systolic volume, EDV
left ventricle end-diastolic volume, MI myocardial infarction
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To get further insight on the protective mechanisms of
TB4, we carried out whole genome gene expression analysis
on cardiac tissue samples. At 2 days post-MI there was sig-
nificant up-regulation of four genes in TB4 treated animals
compared to controls (Table 3.). Two of the genes, start do-
main containing 10 (Stard10) and chitinase 3-like-1 (ch3l1),
have previously been characterized as epicardial signature
genes [10]. CD209f and coiled-coil domain containing 80
(ccdc80) are in turn related to dendritic cell-mediated
endocytosis and modulation of glucose and energy homeos-
tatis, respectively. We also observed up-regulation of some
other epicardial signature genes (uroplakin, dermokine,Fig. 1 Absolute change in EF (a), ESV (b), EDV (c) and MI size (d) between
Representative images of early (e) and late (f) imaging in the same animal.complement components 2 and 3) but these changes
remained statistically insignificant. We validated the up-
regulation of Ch3l1 with qRT-PCR, which showed a 4-fold
increase in mRNA expression at 2 days (p = 0.07) and a 2-
fold increase at 7 days (p < 0.05) post-MI compared to
controls (Fig. 3a). The amount of Ch3l1 positive cells was
slightly higher in TB4 treated animals at 2 (17.8 ± 3.9 cells/
field vs. 22.0 ± 5.6 cells/field, p = 0.34), 5 (19.1 ± 9.5 cells/
field vs. 33.3 ± 14.6, p = 0.23) and 7 days (21.9 ± 11.5 cells/
field vs. 26.7 ± 10.1 cells/field, p = 0.62) after MI but the
differences remained statistically insignificant (Fig. 3b).
ATP/ADP levels and purinergic ecto-enzyme activity
Plasma ATP and ADP levels were similar between the
groups at all time points. There was a slight increase in
ATP and ADP at 7 days post-MI in both groups but
these differences were statistically insignificant com-
pared to earlier time points (Fig. 4a and b). The activity
of soluble ATP and ADP hydrolyzing enzymes remained
unaltered at allthree time points (Fig. 4c and d). The
activity of CD73, which converts AMP to adenosine
increased significantly in TB4 treated animals over time
and was significantly higher at 7 days post-MI compared
to controls (483 ± 47 vs. 643 ± 76 μmol/h/ml, p < 0.05)
(Fig. 4e). The enzymes AK and NDPK, which catalyze
the production of ADP and ATP, showed similar and
consistent levels of activity in all samples (Fig. 4f and g).
Overall NDPK activity was clearly higher than for AK in
both groups.days 2 and 28 in controls and TB4 treated animals (i.p. and i.mc.).
Arrows show the infarct area with LV wall thinning (mean ± SD)
Fig. 2 Histological infarct size a, TUNEL-positive cells b and CD68-positive cells c in controls and TB4 treated animals. Representative images of
the infarct area on HE staining d TUNEL e and IHC for CD68 f 2, 5 and 7 days post MI (mean ± SD)
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TB4 was cardioprotective after both intraperitoneal and
intramyocardial delivery. Local administration seemed to
be more effective although treatment was initiated 2
days later than after systemic administration. This is to
our knowledge the first study comparing early and late
functional and structural parameters and in this manner
demonstrating favorable left ventricle remodeling in
animals treated with TB4 after MI. The effect on left
ventricle dilatation and reduction in EF was however
smaller than in previously reported studies [11, 12]. We
determined infarct sizes by analyzing areas of the LV
showing wall thinning and akinesia. During rest this can
also be related to myocardial stunning. Stress echocardi-
ography would have allowed for more sensitive differen-
tiation between viable and non-viable myocardium but
this is not feasible in rodents. We did however confirm
myocardial scarring with histology. Mortality rates weresimilar between the groups with no survival benefit for
the treated animals. The increased weight gain in controls
compared to TB4 treated animals could be secondary to
LV remodeling and developing heart failure.
On microarray analysis we identified significant up-
regulation of four genes after TB4 treatment. CD209f is
a marker for antigen presenting dendritic cells which
have a crucial role in regulating the inflammatory
response after MI. After MI in humans the amount of
myocardial CD209-positive cells correlates negatively
with ventricular rupture and is associated with increased
reparative fibrosis [13]. TB4 has in preclinical studies
been shown to reduce the incidence of post-infarction
LV rupture. Stard10 is involved in intracellular lipid
transfer and has also been shown to be a signature
epicardial gene that is down-regulated after MI in mice
[10]. Several genes considered epicardial markers were
here up-regulated in TB4 treated animals. This finding
Table 3 Gene expression 2 days after myocardial infarction in controls and TB4 treated animals (top 20 genes)
Gene name Symbol Probe_ID Fold changea adj. p val.
START domain containing 10 Stard10 ILMN_2625601 2.6 <0.05
Chitinase 3-like 1 Chi3l1 ILMN_2609813 2.0 <0.05
Coiled-coil domain containing 80 Ccdc80 ILMN_1234824 2.0 <0.05
CD209f antigen Cd209f ILMN_2699665 1.7 <0.05
Dermokine Dmkn ILMN_3105563 3.1 0.09
Solute carrier family 22 (organic cation transporter), member 1 Slc22a1 ILMN_1248318 3.3 0.10
Nudix (nucleoside diphosphate linked moiety X)-type motif 4;
similar to Nudt4 protein
Nudt4 ILMN_1252730 2.9 0.12
Alpha-2-HS-glycoprotein Ahsg ILMN_2764036 2.2 0.12
Uroplakin 3B Upk3b ILMN_2941714 3.4 0.17
Dickkopf homolog 3 (Xenopus laevis) Dkk3 ILMN_2852957 14.6 0.19
Protein phosphatase 1, regulatory (inhibitor) subunit 1B Ppp1r1b ILMN_2954824 3.2 0.19
Synaptotagmin-like 2 Sytl2 ILMN_3127335 2.3 0.19
Mucin 16 Muc16 ILMN_2631869 1.9 0.19
RAB33A, member of RAS oncogene family Rab33a ILMN_3161828 1.9 0.19
Ficolin A Fcna ILMN_2718589 1.8 0.19
Retinoic acid receptor responder (tazarotene induced) 2 Rarres2 ILMN_3003130 1.8 0.19
WD repeat domain 92 Wdr92 ILMN_1225370 3.1 0.20
Complement component 2 (within H-2S) C2 ILMN_2612895 2.3 0.20
Complement component 3; similar to complement component
C3 prepropeptide, last
C3 ILMN_2759484 2.1 0.22
Double C2, gamma Doc2g ILMN_2704429 1.8 0.24
mRNA expression analyzed by Illumina microarray (MouseWG-6 v2.0). P-values were adjusted by the Benjamini-Hochberg method
aTB4 versus control
Fig. 3 Chitinase 3-like-1 mRNA expression a by qRT-PCR and Ch3l1 positive cells b in controls and TB4 treated animals. Representative IHC images
for Ch3l1 in the non-infarcted myocardium and infarct area 5 days and 28 days post-MI c (mean ± SD)
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Fig. 4 Plasma ATP (a) and ADP (b) levels in controls and TB4 treated animals. Activity of hydrolyzing enzymes ATPase (c), ADPase (d) and
5’-ecto-nucleotidase or CD73 (e) in plasma of controls and TB4 treated animals. Enzymatic activity of kinases NDPK f and AK g in plasma of
controls and TB4 treated animals (mean ± SD)
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epicardial progenitor cell activation.
Ch3l1 or YKL-40 is a chitin binding protein secreted
by macrophages, neutrophils and vascular smooth
muscle cells and has recently gathered attention as a
marker for inflammation and fibrosis [14]. We verified
its up-regulation on microarray analysis by RT-PCR,
where mRNA levels for Ch3l1 were higher in treated
animals at days 2 and 7 post-MI compared to controls.
Immunohistochemistry for Ch3l1 showed slightly more
positive cells in the infarct area of TB4 treated animals
at all time points. The positive cells located within the
infarct area and could represent inflammatory cells,
either macrophages or leukocytes. Positive staining for
Ch3l1 was still observed 28 days after MI and the posi-
tive cells located in the fibrotic centre of the infarct area.
Quantification of these cells was not performed because
the positive cells were arranged densely without clear-
cut borders making it challenging to recognize individual
cells on conventional ICH staining. In previous trials
increased plasma levels of Ch3l1 has been found inpatients during the first week after myocardial infarction
and in some reports this elevation was still observed 1
month after the event. One study showed a negative
correlation between maximal Ch3l1 levels and left ven-
tricular EF recovery after MI. In patients receiving
granulocyte-colony stimulating factor treatment there
was an increase in plasma Ch3l1 but no correlation with
cardiac recovery [15]. Patients suffering from MI often
have several co-morbidities and are in a state of chronic
inflammation. Direct comparison between MI patients
and otherwise healthy laboratory animals is troublesome
as the source of Ch3l1 is likely different. In our study
peak mRNA expression for Ch3l1 was observed in TB4
treated animals 2 days after MI and remained higher at
day 7 post-MI and the increase was also seen on histology.
The different profile in Ch3l1 expression in the two
groups could be related to TB4-mediated modification of
the inflammatory response after MI. Ch3l1 binds to
PAR2-receptors, which are expressed on cardiomyocytes
but also on inflammatory cells. Ch3l1 treatment is associ-
ated with cardiomyocyte hypertrophy in vitro and has
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[16]. Pharmacological PAR2 activation offers cardioprotec-
tion after cardiac ischemia-reperfusion injury by reducing
reactive oxygen species and inflammation [17]. TB4 in
turn, increases Akt phosphorylation by acting through the
focal adhesion complex [2]. The combined effects of TB4
and Ch3l1 could in theory enhance Akt-mediated sig-
naling and further improve cardiomyocyte survival.
There were no differences in cardiomyocyte apoptosis
or influx of CD68 positive macrophages during the first
week after MI. The incidence of apoptotic cells decreased
steadily between days 2 and 7. Measuring apoptosis at an
earlier time point might have highlighted some differences
between the groups. The amount of CD68 positive cells
increased gradually from day 2 to day 7 after MI without
differences between groups. In a previous study, it was
reported that the peak influx of macrophages occurred 4
days after MI in TB4 treated mice and then decreased
rapidly by day 7 [18]. The authors used a marker for M1
polarized macrophages as we also did in the present study.
Therefore, the decrease in positive cells could also have
been related to a switch in phenotype rather than a true
decrease in macrophage number. We did not further
investigate the phenotype of the cells in this study. This
could have been valuable in order to identify pro-
inflammatory (M1) and cardioprotective or reparative
(M2) macrophages as Ch3l1 has previously been shown to
play a role in M2 macrophage activation [19].
Recently it was reported that TB4 increases extracellu-
lar ATP synthesis and possibly induces purine receptor-
mediated endothelial cell migration [3]. This encouraged
us to screen plasma samples for ATP and ADP and for
activities of soluble purine-converting enzymes. ATP is
not able to diffuse across the cell membrane but is re-
leased after cellular damage or through several different
transporters. In the heart ATP acts mainly on P2-recep-
tors causing vasoconstriction and increased inotropy,
but can also induce arrhythmias. ATP is a powerful
chemoattractant for leukocytes and signaling through
P2x7-receptors induces inflammatory and apoptotic path-
ways [20]. In order to control ATP-mediated signaling,
ATP is metabolized to ADP and further to AMP by dif-
ferent hydrolyzing enzymes, collectively called ATPases
and ADPases. AMP in turn is hydrolyzed to adenosine
by CD73. ADP is able to reduce ischemic damage in the
heart by acting on P2y-receptors but is also a key trans-
mitter in thrombosis formation. Adenosine in turn has
showed several cardioprotective properties [18]. In this
study plasma ATP and ADP levels were similar between
the groups with a trend for higher overall levels at day 7
post MI. ATPase and ADPase activities were consistent
during the first week. In TB4 treated animals the activity
of CD73 continued to increase from day 2 to day 7 after
infarction and at day 7 the activity was significantlyhigher than in controls. After myocardial damage,
mainly inflammatory cell-derived CD73 is responsible
for the local increase in Adenosine. This CD73-derived
adenosine in turn reduces inflammation and can also
enhance the activation of anti-inflammatory M2 macro-
phages, possibly suppressing the inflammatory reaction
further [21]. Based on these findings, TB4’s influence on
purinergic signaling may not be limited to ATP synthase
but might also involve other enzymes.
Limitations
In this study, we did not measure activities of known
TB4-related pathways such as Akt phosphorylation nor
did we directly measure adenosine concentrations. We
did however demonstrate efficacy and displayed a thera-
peutic window for TB4 therapy 2 to 28 days after MI. In
spite of small sample sizes in the short term study we
were able to demonstrate significant changes in some of
the parameters measured. These are however only obser-
vations and the underlying mechanisms will still have to
be addressed in the future. We did not record infarct
area but used infarct length as an endpoint in order to
obtain comparable values between echocardiographic
and histological measurements.
Conclusions
TB4 treatment reduced cardiac remodeling and improved
function after MI. We can only speculate whether our
findings on Ch3l1 up-regulation and increased CD73 ac-
tivity are directly related to the therapeutic effects of TB4.
There are however several common pathways for these
molecules and this will provide interesting hypotheses for
future studies.
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